TrialThe lancet. HIV2018
Subtype C ALVAC-HIV and bivalent subtype C gp120/MF59 HIV-1 vaccine in low-risk, HIV-uninfected, South African adults: a phase 1/2 trial.
Linda-Gail Bekker et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
78 papers cite itlatest 60 shown
this paperpooled ittrialcites it